$298.25
1.89% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US58506Q1094
Symbol
MEDP

Medpace Stock News

Positive
The Motley Fool
17 days ago
Explore the exciting world of Medpace Holdings (MEDP 1.11%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
Seeking Alpha
about 2 months ago
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Ann Hynes - Mizuho Dan Leonard - UBS Eric Coldwe...
Negative
Investors Business Daily
about 2 months ago
Medpace stock tumbled Tuesday after lighter-than-expected bookings in the March quarter "cast more doubt on the path forward."
Neutral
Business Wire
about 2 months ago
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue for the three months ended March 31, 2025 increased 9.3% to $558.6 million, compared to $511.0 million for the comparable prior-year period. On a constant currency basis, revenue for the first qu...
Positive
The Motley Fool
2 months ago
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.
Neutral
Seeking Alpha
2 months ago
Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high.
Neutral
Business Wire
3 months ago
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties mus...
Neutral
Seeking Alpha
4 months ago
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q4 2024 Earnings Conference Call February 11, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Max Smock - William Blair Eric Coldwell - Baird David Windley - Jefferies Jaile...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today